Table 3.
Proportion of trials reporting patient-important outcomes as primary outcomes, stratified by trial characteristics*
| Outcome | Trial characteristic; no. (%)† | ||||
|---|---|---|---|---|---|
| All trials | Superiority trials | Noninferiority trials | Full or partial industry funding | Nonindustry funding | |
| No. of trials | 225 | 212 | 13 | 58 | 58 |
| Any patient-important outcome | 148 (66) | 139 (66) | 9 (69) | 35 (60) | 34 (59) |
| Mortality/survival | 10 (4) | 10 (5) | 0 | 0 | 2 (3) |
| Pain | 20 (9) | 20 (9) | 0 | 4 (7) | 4 (7) |
| Function | 24 (11) | 23 (11) | 1 (8) | 9 (16) | 4 (7) |
| Quality of life | 8 (4) | 7 (3) | 1 (8) | 3 (5) | 2 (3) |
| Morbid events or symptoms | 92 (41) | 86 (41) | 7 (54) | 20 (34) | 22 (38) |
| Patient satisfaction | 1 (0.4) | 1 (0.5) | 0 | 0 | 0 |
| Intervention outcomes | 25 (11) | 25 (12) | 0 | 7 (12) | 8 (14) |
| Surrogate outcomes | 74 (33) | 71 (33) | 3 (23) | 25 (43) | 20 (34) |
| Laboratory outcomes | 17 (8) | 15 (7) | 2 (15) | 5 (9) | 3 (5) |
*
Data presented only from trials that explicitly specified a primary outcome. Some trials reported more than 1 primary outcome, hence the classifications were not mutually exclusive.
†
Unless indicated otherwise.